- cafead Jun 13, 2024 at 11:13: AM
via Palatin Technologies has commenced a Phase II clinical trial of breatelanotide, a melanocortin 4 receptor (MC4R) agonist, to treat obesity.
The trial, which has received clearance from the Food and Drug Administration (FDA), aims to investigate the effectiveness, safety and tolerability of bremelanotide when co-administered with tirzepatide, a GLP-1/GIP therapy, in obese patients.
article source
The trial, which has received clearance from the Food and Drug Administration (FDA), aims to investigate the effectiveness, safety and tolerability of bremelanotide when co-administered with tirzepatide, a GLP-1/GIP therapy, in obese patients.
article source